AKT1 and cancer: More recently, it has been shown that exosomal transference of wild-type EGFR to EGFR-mutated sensitive cancer cells promotes resistance to the mutant-selective EGFR inhibitor osimertinib by activating the MAPK and PI3K/AKT signaling pathways[146].